I agree with mcbio because I would suggest that the market often ascribes significantly too much value to early products with unproven, or even mildly disproven, management. This is a corollary of a more general version of the Feurstein Ratain rule (the rule, as they strictly wrote it, applies only to onc companies - but I think a more general version to cover all biotech).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.